Tsung-Hui Li

Title: Tsung-Hui Li: Innovator in Pharmaceutical Chemistry

Introduction

Tsung-Hui Li is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific receptor tyrosine kinases and tubulin inhibitors.

Latest Patents

Li holds two notable patents. The first patent involves heterocycle compounds as Tyro3, Axl, and MerTK family of receptor tyrosine kinase inhibitors. This patent discloses compounds of formula (I) and their various forms, including tautomers and stereoisomers. It also outlines methods for treating diseases mediated by these kinases using the disclosed compounds. The second patent focuses on tubulin inhibitors and methods of using them. These compounds, represented by formula (I), are designed to inhibit tubulin polymerization and are useful in treating tumors and other conditions associated with abnormal cell proliferation.

Career Highlights

Tsung-Hui Li is affiliated with the Development Center for Biotechnology, where he continues to advance his research and innovation in pharmaceutical compounds. His work has the potential to impact the treatment of various diseases significantly.

Collaborations

Li collaborates with notable colleagues, including Meng-Hsin Chen and Shih-Hsien Chuang, contributing to a dynamic research environment that fosters innovation.

Conclusion

Tsung-Hui Li's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in medical treatments.